| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 208,50 | 211,50 | 16:04 | |
| 0,000 | 0,000 | 14:00 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.12. | ResMed stock price target lowered to $260 by Stifel on Philips return concerns | 16 | Investing.com | ||
| 16.12. | Tandem Diabetes upgraded, Zimmer, ResMed downgraded as Baird previews MedTech in 2026 | 4 | Seeking Alpha | ||
| 16.12. | Baird stuft ResMed-Aktie wegen Wachstumssorgen auf "Neutral" herab | 18 | Investing.com Deutsch | ||
| 16.12. | Baird downgrades ResMed stock rating to Neutral on slowing growth | 7 | Investing.com | ||
| 12.12. | UBS erhöht Kursziel für ResMed auf 345 US-Dollar | 4 | Investing.com Deutsch | ||
| 09.12. | RESMED INC: 4 Statement of changes in beneficial ownership | 2 | ASX | ||
| 09.12. | RESMED INC: 144 Report of proposed sale of securities | 1 | ASX | ||
| RESMED Aktie jetzt für 0€ handeln | |||||
| 08.12. | Resmed Gets FDA Clearance For Personalized Therapy Comfort Settings; To Be Marketed As Smart Comfort | 562 | AFX News | WASHINGTON (dpa-AFX) - Resmed (RMD, RMD.AX), Monday announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed... ► Artikel lesen | |
| 08.12. | Resmed wins FDA clearance for AI-enabled personalized CPAP therapy device | 3 | MassDevice | ||
| 08.12. | Resmed, Inc.: Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy | 364 | GlobeNewswire (Europe) | SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has... ► Artikel lesen | |
| 08.12. | Is ResMed Stock Underperforming the S&P 500? | 5 | Barchart.com | ||
| 05.12. | Healthcare & Biotech Stocks Rally After Hours: Sensei, Praxis, Cooper, Vanda, Cue, ResMed | 500 | AFX News | WASHINGTON (dpa-AFX) - Several healthcare and biotech names posted notable gains in Thursday's after-hours session, driven by clinical updates, earnings results, and regulatory developments.Sensei... ► Artikel lesen | |
| 04.12. | RESMED INC: 4 Statement of changes in beneficial ownership | 1 | ASX | ||
| 04.12. | RESMED INC: 144 Report of proposed sale of securities | - | ASX | ||
| 03.12. | RESMED INC: Statement of CDIs on issue - RMD | 6 | ASX | ||
| 02.12. | RESMED INC: 144 Report of proposed sale of securities | - | ASX | ||
| 01.12. | RESMED INC: 144 Report of proposed sale of securities | - | ASX | ||
| 27.11. | PETER FARRELL At ResMed Acquires Stock Options Worth $7K | 19 | Benzinga.com | ||
| 27.11. | Michael J Farrell Makes Strategic Play: Invests $179K In ResMed Stock Options | 9 | Benzinga.com | ||
| 26.11. | RESMED INC: 4 Statement of changes in beneficial ownership | 11 | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 48,980 | +0,60 % | Amneal Pharma, MAbxience: FDA Approves Denosumab Biosimilars Referencing Amgen's Prolia And XGEVA | THOUSAND OAKS (dpa-AFX) - Amneal Pharmaceuticals, Inc. (AMRX) announced late Monday that the U.S. Food and Drug Administration has approved the Biologics Licensing Applications or BLAs for Boncresa... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,760 | +0,37 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 44,920 | +0,54 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Siemens Healthineers vor Zahlen zum ersten Geschäftsquartal auf "Buy" mit einem Kursziel von 60 Euro belassen. Der Medizintechnikkonzern... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 40,000 | -1,57 % | CARL ZEISS MEDITEC AG stürzt ab - Panik im TecDAX! | ||
| ECKERT & ZIEGLER | 15,260 | -0,13 % | ECKERT & ZIEGLER SE zündet heute den Kursturbo! | ||
| UNITEDHEALTH | 280,10 | +0,23 % | 3 Risks That Can Make UnitedHealth Stock Unattractive | ||
| DRAEGERWERK | 69,40 | +0,14 % | EQS-News: Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener Aktien - Abschlussmeldung | EQS-News: Drägerwerk AG & Co. KGaA
/ Schlagwort(e): Sonstiges
Drägerwerk AG & Co. KGaA: Bekanntmachung nach Art. 5 Abs. 1 und Abs. 3 der Verordnung (EU) Nr. 596/2014: Erwerb eigener... ► Artikel lesen | |
| MEDTRONIC | 81,58 | -0,13 % | Dividendenbekanntmachungen (26.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALERUS FINANCIAL CORPORATION US01446U1034 0,21 USD 0,1782 EUR ALTRIA GROUP INC US02209S1033 1,06 USD 0,8999 EUR ARROWMARK FINANCIAL... ► Artikel lesen | |
| GERRESHEIMER | 27,580 | 0,00 % | Comeback 2026! Verzehnfachung möglich? Evotec, Gerresheimer, Desert Gold Aktie! | Auf der Suche nach einem möglichen Verzehnfacher im Gold-Sektor? Dies halten Analysten bei Desert Gold für möglich. Die jüngste PEA für das Flaggschiff-Gold-Projekt löst neue Kursfantasie aus. Damit... ► Artikel lesen | |
| INTUITIVE SURGICAL | 486,45 | -0,50 % | Is ISRG's 20% Procedure Growth the New Normal or a Peak? | ||
| THERMO FISHER | 492,35 | -0,95 % | What to Expect From Thermo Fisher Scientific's Next Quarterly Earnings Report | ||
| TELADOC HEALTH | 5,901 | +0,31 % | HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling? | ||
| STRATEC | 22,450 | -0,22 % | Aktien Frankfurt: Dax vorweihnachtlich träge | FRANKFURT (dpa-AFX) - Nach den moderaten Gewinnen am Freitag ist der deutsche Aktienmarkt etwas schwächer in die kurze Handelswoche vor Weihnachten gestartet. Das Geschehen ist von einem deutlich geringeren... ► Artikel lesen | |
| GENEDX | 128,45 | -0,69 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen | |
| PROGYNY | 25,780 | +0,62 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen |